Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of BI 671800 Salt Forms and Formulations
NCT02221388Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Feb 2010
- Primary completion
- Jul 2010
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, open-label trial of BI-671800 in asthma and seasonal allergic rhinitis (SAR) (6 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Maximum measured concentration in plasma at 24 hours and Area under the concentration-time curve extrapolated to infinity at 24 hours. Started Feb 2010; status: completed.
02
Drugs
BI-671800
03
Conditions
asthmaseasonal allergic rhinitis (SAR)
Beyond the preview
Go deeper on NCT02221388.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02221388.